BUSINESS SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Summary of Segment Reporting Information by Segment

The following table is a summary of segment information for the three and nine months ended September 30, 2022 and 2021. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating

earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2021 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenues:
DIS business	$	2,419	$	2,703	$	7,344	$	7,820
All other operating segments	67		71		206		224
Total net revenues	$	2,486	$	2,774	$	7,550	$	8,044
Operating earnings (loss):
DIS business	$	441	$	713	$	1,445	$	2,026
All other operating segments	3		8		16		26
General corporate activities	(52)		(69)		(168)		(207)
Total operating income	392		652		1,293		1,845
Non-operating (expense) income, net	(41)		2		(167)		252
Income before income taxes and equity in earnings of equity method investees	351		654		1,126		2,097
Income tax expense	(81)		(153)		(268)		(483)
Equity in earnings of equity method investees, net of taxes	6		26		41		53
Net income	276		527		899		1,667
Less: Net income attributable to noncontrolling interests	20		22		54		62
Net income attributable to Quest Diagnostics	$	256	$	505	$	845	$	1,605

Schedule of Revenues by Major Service

Net revenues by major service were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Routine clinical testing and other services	$	1,119	$	1,210	$	3,283	$	3,392
COVID-19 testing services	316		709		1,270		2,048
Gene-based and esoteric (including advanced diagnostics) testing services	835		646		2,361		1,972
Anatomic pathology testing services	149		138		430		408
All other	67		71		206		224
Total net revenues	$	2,486	$	2,774	$	7,550	$	8,044